Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Privosegtor

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oculis To Present At North American Neuro-Ophthalmology Society
    Oculis To Present At North American Neuro-Ophthalmology Society

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256033/0/en/Oculis-to-Present-at-Upcoming-North-American-Neuro-Ophthalmology-Society-Annual-Meeting.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Oculis To Participate In Upcoming Investor Conferences
    Oculis To Participate In Upcoming Investor Conferences

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249883/0/en/Oculis-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Oculis Reports 2025 Financial Results And Company Update
    Oculis Reports 2025 Financial Results And Company Update

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248901/0/en/Oculis-Reports-Q4-and-Full-Year-2025-Financial-Results-and-Provides-Company-Update.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Oculis Receives FDA Breakthrough Designation For Privosegtor
    Oculis Receives FDA Breakthrough Designation For Privosegtor

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213346/0/en/Oculis-Announces-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-Privosegtor-for-Treatment-of-Optic-Neuritis.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Oculis To Participate In Upcoming November Investor Conferences
    Oculis To Participate In Upcoming November Investor Conferences

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181132/0/en/Oculis-to-Participate-in-Upcoming-November-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Oculis Announces Oversubscribed $110 Million Financing
    Oculis Announces Oversubscribed $110 Million Financing

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177102/0/en/Oculis-Announces-Oversubscribed-110-Million-Financing-to-Accelerate-Privosegtor-Development.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.